drugset
drugset / Trial / NCT04940949

A Study to Evaluate Lu AF90103 in Healthy Men

NCT04940949 ↗

Phase 1 Terminated 15 enrolled H. Lundbeck A/S
RandomizedSequentialDouble-blindTreatment

Summary

The purpose of this study is to investigate the safety and tolerability of Lu AF90103 and what the body does to Lu AF90103 after single doses of the drug administered directly into a vein.

Timeline

Start
2021-05-26
Primary completion
2021-11-23
Completion
2021-11-23

Outcome

Outcome not reported

Stopped: “The study was terminated based on new safety data.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Lu AF90103 Unknown — Intravenous

Indications

No indication recorded.